RE: RE: RE: Just a thought...Technicalbuy.. Sinbob, you've provided a lot of insight. Thank you. I'll quickly speak to some of the points you've raised.
The vehicle you refer to is a protein "p97", that is able to cross the bbb. When combined with a drug (like Hercepting for example) it in essence forms a new drug which, as you've indicated, will have to go through FDA approval process like any other new drug.
Why is Bioasis exciting now, despite the fact that for any commercial drugs we have a long road ahead?
One answer is in example that I mentioned in my article: "Seattle Genetics and Abbott, under which Abbott paid $8M up front for rights to utilize Seattle Genetics' antibody-drug conjugate technology rights for a single oncology target."
This company was paid up front $8M, at the start of clinical trials.
Bioasis can follow the same model for hundreds, if not thousands, of applicaple drugs. That means tens of millions of dollars in revenue in the next few years in up-front and milestone payments, and billions of dollars in revenue in royalties down the road (all things being equal).
Different drugs are valued differently. But I would say that when it comes to crossing the bbb, we're probably in one of the most sought after (lucrative) market segments.
Over the years I've seen companies with rare disease market drugs in Phase I, and even pre-clinical stage, get taken out. Based on this, and for all of the reasons mentioned above, I think there is a good chance that Bioasis will be taken over by one of the top 50 pharmas this year.
That is why BTI is exciting under $1. Sky's the limit.
TB